The Cochlear (ASX:COH) share price is down 8% in 4 weeks. Is it a buy?

Is it time to buy this healthcare share?

| More on:
person thinking with another person's hand drawing a question mark on a blackboard in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Limited (ASX: COH) share price has been a positive performer on Wednesday.

In afternoon trade, the hearing solutions company's shares are up over 2% to $235.39.

This means the Cochlear share price is now up 24% since the start of the year. This is despite its shares falling 8% over the last four weeks.

Is the Cochlear share price good value?

One top broker is likely to see the recent pullback in the Cochlear share price as a buying opportunity for investors.

In response to the company's full year results last month, the team at Macquarie Group Ltd (ASX: MQG) retained their outperform rating but trimmed their price target on its shares by 3% to $256.00.

Based on the current Cochlear share price, this suggests there's still approximately 9% upside over the next 12 months.

What did the broker say?

According to the note, Macquarie was pleased with the company's performance in FY 2021.

For the 12 months ended 30 June, Cochlear reported a 10% increase in sales revenue to $1,493.3 million and a 54% jump in underlying net profit to $236.7 million. The latter was in line with Macquarie's expectations and also the company's guidance of $225 million to $245 million.

However, one thing that did fall short was the company's guidance for FY 2022. Cochlear is expecting net profit growth of 12% to 20% for the year ahead.

Macquarie was expecting stronger growth, which led to its analysts revising its earnings per share estimate for FY 2022 down by approximately 11%.

Nevertheless, the broker remains positive on the company's outlook and the Cochlear share price. This is due to its belief that the company is positively leveraged to a post-pandemic recovery in activity levels.

Macquarie also noted recently that its survey of US based audiologists was very favourable. Its survey found that Cochlear's products were the highest rated in the industry and met key criteria for both adult and paediatric patients. As a result, the company is expected to grow its market share over the next 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Cochlear Ltd. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Broker Notes

This ASX All Ords stock is undervalued and could rocket 60%+

Bell Potter is tipping this share to deliver big returns for investors.

Read more »

High fashion look. glamor closeup portrait of beautiful sexy stylish Caucasian young woman model with bright makeup, with red lips, with perfect clean skin.
Broker Notes

2 ASX All Ords shares top brokers rate as a 'buy'

See what the latest is for these two names.

Read more »

A cool young man walking in a laneway holding a takeaway coffee in one hand and his phone in the other reacts with surprise as he reads the latest news on his mobile phone
Broker Notes

This ASX 200 share is one of 'the highest quality businesses on the ASX'

Let's see which stock analysts at Wilsons rate incredibly highly right now.

Read more »

Young woman in yellow striped top with laptop raises arm in victory
Broker Notes

Buy this ASX 300 stock for 20% upside and a 6% yield

Analysts at Bell Potter think investors should be buying this stock before it's too late.

Read more »

young woman reviewing financial reports at desk with multiple computer screens
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these stocks.

Read more »

Woman in celebratory fist move looking at phone
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Broker Notes

These ASX 200 shares could rise 20% to almost 30%

Analysts are tipping these shares to deliver big returns over the next 12 months.

Read more »

Two people tired and resting after sports race.
Broker Notes

Fundie rates 2 ASX 200 stocks in short-term pain but with long-term gain potential

Blackwattle Investment Partners sees these 2 ASX 200 stocks as worthy of a buy and hold strategy.

Read more »